Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:gadolinium_complex
gptkb:contrast_agent |
| gptkbp:approvalYear |
1988
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
V08CA01
|
| gptkbp:brand |
gptkb:Magnevist
|
| gptkbp:CASNumber |
86050-77-3
|
| gptkbp:containsElement |
gptkb:gadolinium
|
| gptkbp:contraindication |
severe renal impairment
|
| gptkbp:discoveredBy |
gptkb:Schering_AG
|
| gptkbp:eliminationHalfLife |
1.6 hours
|
| gptkbp:excretion |
renal
|
| gptkbp:hasMolecularFormula |
C28H54GdN5O20
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:riskFactor |
gptkb:nephrogenic_systemic_fibrosis
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
nausea
headache allergic reaction |
| gptkbp:usedFor |
magnetic resonance imaging
|
| gptkbp:bfsParent |
gptkb:Magnevist
gptkb:gadolinium-based_contrast_agents |
| gptkbp:bfsLayer |
7
|
| https://www.w3.org/2000/01/rdf-schema#label |
gadopentetate dimeglumine
|